AVALO THERAPEUTICS, INC. — Operating Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/513f60ac-a028-4336-b755-b3cca18f0e77/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-72.9M | 2025-01-01 – 2025-12-31 | evidence 0001534120-26-000011 |
| FY 2024 | $-68.5M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-013986 |
| FY 2023 | $-27.4M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-013786 |
| FY 2022 | $-37.4M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-009630 |
| FY 2021 | $-82.1M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-004671 |
| FY 2020 | $-72.8M | 2020-01-01 – 2020-12-31 | evidence 0001628280-22-004671 |
| FY 2019 | $-16.1M | 2019-01-01 – 2019-12-31 | evidence 0001628280-20-003395 |
| FY 2018 | $-35.4M | 2018-01-01 – 2018-12-31 | evidence 0001628280-20-003395 |
| FY 2017 | $13.9M | 2017-01-01 – 2017-12-31 | evidence 0001628280-18-003890 |
| FY 2016 | $-16.1M | 2016-01-01 – 2016-12-31 | evidence 0001628280-17-002566 |
| FY 2015 | $-11.0M | 2015-01-01 – 2015-12-31 | evidence 0001558370-16-004299 |
| FY 2014 | $-17.1M | 2014-01-01 – 2014-12-31 | evidence 0001558370-16-004299 |
| FY 2013 | $-12.9M | 2013-01-01 – 2013-12-31 | evidence 0001558370-16-004299 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).